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Abstract
Inhaled adenosine receptor agonists induce bronchoconstriction and inflammation in asthma and are used as bronchial challenge
agents for the diagnosis of asthma and in respiratory drug development. Recently developed dry powder aerosols of adenosine
have several advantages over nebulised adenosine 5′-monophosphate (AMP) as bronchial challenge agents. However, reverse
translation of this bronchial challenge technique to pre-clinical drug development is limited by the difficulty of administering
powder aerosols to animals. The aim of the current study was to develop methods for delivering powder aerosols of adenosine
receptor agonists to sensitised guinea pigs (as a model of allergic asthma) and evaluate their effect as challenge agents for the
measurement of airway responsiveness. The PreciseInhale system delivered micronised AMP and adenosine powders, with mass
median aerodynamic diameters of 1.81 and 3.21 μm and deposition fractions of 31 and 48% in the lungs, respectively.
Bronchoconstrictor responses in passively sensitised, anaesthetised, spontaneously breathing guinea pigs were compared to
responses to nebulised and intravenously administered AMP and adenosine. AMP- and adenosine-induced bronchoconstriction
following all routes of administration with the magnitude of response ranking intravenous > dry powder > nebulisation, probably
reflecting differences in exposure to the adenosine agonists delivered by the different routes. In conclusion, the PreciseInhale
system delivered AMP and adenosine dry powder aerosols accurately into the lungs, suggesting this method can be used to
investigate drug effects on airway responsiveness.
Keywords Adenosine . Adenosine 5′-monophosphate . Bronchoconstriction . Asthma . Drug development
Dry powder inhalation
Introduction
Airway hyperresponsiveness (AHR) is present in nearly all
patients with asthma and in many patients with chronic
obstructive pulmonary disease (COPD) [1]. AHR is an in-
crease in the sensitivity and reactivity of the airways in re-
sponse to airway exposure to nonspecific stimuli and is com-
monly measured by means of a bronchial challenge test [2, 3].
The gold standard challenge agent for quantifying AHR is
methacholine which acts directly on airway smooth muscle
cells [4]. However, use of the indirectly acting stimulus aden-
osine may provide diagnostic benefits since AHR to adeno-
sine is more mechanistically representative of the disease pa-
thology and airway inflammation than AHR to methacholine
[5, 6]. On this basis, it has been argued persuasively that aden-
osine bronchial challenge testing is a better non-invasive tool
for monitoring disease activity and an improved method for
assessing the response to anti-inflammatory treatments [7].
Moreover, recent findings suggest that bronchial challenging
with adenosine may improve diagnostic discrimination be-
tween asthma and COPD [8].
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Until recently, the only way to deliver adenosine to the
lungs was by means of nebulisation for which solutions of
adenosine 5′-monophosphate (AMP) rather than adenosine
itself have been used because of AMP’s higher aqueous sol-
ubility. Following inhalation, AMP is rapidly hydrolysed to
adenosine by 5′-nucleotidase. However, nebulisation of
AMP has a number of drawbacks. First, the maximum aero-
sol droplet AMP concentration (300–400 mg/mL; restricted
by the nebuliser solution’s viscosity) does not result in AHR
in all patients [8, 9]. Furthermore, nebuliser solution AMP
concentrations > 20 mg/mL have been shown to greatly af-
fect aerosol formation, which may have implications for the
test outcome, such as a shift in deposition site or dispropor-
tional dose increase [10]. Delivery of adenosine as a dry
powder aerosol overcomes the issues identified above [11,
12], and bronchial challenge in subjects with asthma has
demonstrated that adenosine and AMP appear to induce air-
way obstruction in a similar manner [13]. Based on these
findings, we reasoned that if dry powder adenosine is useful
clinically as an inducer of airway obstruction, this should be
reverse translated into pre-clinical models to provide more
relevant test systems for studying asthma pathophysiology
and to aid in the development of novel drug treatments for
affecting AHR.
The aim of this study therefore was to develop improved
methods to deliver adenosine receptor agonist powder aero-
sols to sensitised guinea pigs (as a model of allergic asthma) to
measure airway responsiveness. In this feasibility/proof-of-
concept study, we have investigated whether administration
of dry powder aerosols of adenosine agonists can be used to
induce airway obstruction in a pre-clinical model of allergic
asthma. Our group has previously shown that nebulised AMP
and N6-cyclopentyladenosine (CPA; an adenosine A1 receptor
agonist) induce airway obstruction in allergic, but not naïve,
guinea pigs that were anaesthetised and artificially ventilated
[14]. However, the urethane-induced anaesthesia used in these
studies can suppress respiration and thus does not allow ani-
mals to breathe spontaneously with sufficient tidal volume to
permit inhalation of a dry powder aerosol. Therefore, we first
needed to develop a new anaesthetic regime to allow aerosols
to be inhaled by spontaneously breathing, unconscious guinea
pigs. To deliver the dry powder, we utilised a relatively new
technique to administer dry powder aerosols to animals, the
PreciseInhale system (Inhalation Sciences, Sweden). This sys-
tem generates a dispersed aerosol cloud approaching the pri-
mary particle size of the powder, which is delivered to an
individual animal with minimised loss of drug and accurate
computer-controlled dose administration [15, 16]. The current
paper describes the novel anaesthetic regime, evaluates the use
of the PreciseInhale system for delivering adenosine receptor
agonist powders to sensitised guinea pigs and compares the
resultant bronchial obstruction with that produced by
nebulisation and intravenous delivery of the same agents.
Materials and methods
Drugs
The following reagents were used in this study: adenosine,
adenosine 5′-monophosphate (AMP), ovalbumin (grade V),
urethane (all Sigma-Aldrich, UK), propofol, isoflurane
(Centaur Services, UK) and the selective adenosine A1 recep-
tor agonist N6-cyclopentyladenosine (CPA) (Tocris, UK).
Dry powder aerosol preparation
Spray drying
Spray-dried powders of adenosine and AMP were prepared
following the same procedure used for the adenosine powders
that were tested clinically [11]. Aqueous solutions of adeno-
sine or AMP at a concentration of 25 mg/mL were spray dried
with a Büchi B290 Mini Spray Drier (Büchi Labortechnik,
Switzerland) under the following conditions: compressed ni-
trogen flow rate 650 L/h, aspirator 100%, solution feed rate
2.5 mL/min, inlet temperature 120 °C, nozzle size 0.7 mm.
The outlet temperature was around 73 °C. The adenosine so-
lution was kept at 50 °C during spray drying to prevent pre-
cipitation of the solute.
Micronisation
Adenosine, AMP and CPAwere micronised using an Alpine
AS 50 jet mill (Hosakawa, Germany). For adenosine and
AMP, a nozzle pressure of 3 bar and a milling pressure of
1 bar were applied. Adenosine was micronised twice using
the same settings to obtain a powder with the desired particle
size. CPA was micronised by applying a nozzle pressure of
1.5 bar and a milling pressure of 0.5 bar.
Primary particle size analysis
The primary particle size distributions (PSDs) of the
micronised and spray-dried adenosine receptor agonists were
measured with a HELOS BR laser diffraction apparatus
(Sympatec, Germany) using a 100-mm (R3) lens and the
FREE calculation mode based on the Fraunhofer theory. The
powders were dispersed with a RODOS disperser at 3 bar
(Sympatec). All measurements were performed in duplicate.
Solid-state characterisation
The effects of micronisation and spray drying on the solid-
state properties of the adenosine receptor agonists were inves-
tigated with differential scanning calorimetry (DSC) and X-
ray powder diffraction (XRPD) analysis. Thermal analysis
characterising physical transformations was performed with
Drug Deliv. and Transl. Res. (2018) 8:760–769 761
a DSCQ2000 (TA Instruments, Belgium). Samples of 2–5mg
were weighed in open aluminium pans. Samples were
preheated at 70 °C for 10 min to remove any adsorbed water
and subsequently heated from 0 to 150 or 200 °C (CPA) or
260 °C (adenosine and AMP) at a rate of 20 °C per minute. X-
ray diffraction patterns were determined using a D2 Phaser
diffractometer (Bruker, the Netherlands) at a scanning rate of
0.004°/min over a 2θ range of 5–60° using a 30-kV voltage
and a 10-mA current.
Dry powder dispersion using the PreciseInhale system
Dry powder aerosols were generated with the PreciseInhale
system which has been described in detail previously [17].
Briefly, a powder sample is loaded into the dosing chamber
and then vertically ejected by means of a short high-pressure
air jet through a nozzle into a cylindrical holding chamber.
From here, the aerosol is transferred by airflow to the animal
or collected for analysis. The rate of aerosol transfer is con-
trolled by either superimposed over- and/or under-pressure
created downstream by a vacuum pump (or by a subject’s
inhalation). A schematic representation of the PreciseInhale
system is shown in Fig. 1.
Powder samples were loaded into the PreciseInhale dosing
chamber in accurately weighed doses of approximately 1 mg
(spray-dried AMP, spray-dried, and micronised adenosine) or
0.7 mg (micronised AMP and CPA). These quantities were
found to generate the highest emitted fraction from the system
with minimal risk of nozzle blockage. The system tracks the
emitted dose during the measurement by means of a light
scattering signal (Casella Microdust Pro, Casella CEL Inc.,
Buffalo, NY, USA), which is calibrated against the inhaled
mass of the test substance [16]. As multiple doses are needed
to obtain the full dose for an animal, differences in loaded dose
have no implications for the administration.
The aerodynamic PSD of the aerosol was determined by cas-
cade impaction analysis using the PreciseInhale system with a
Marple cascade impactor (MSP Corp., Shoreview, MN, USA)
attached to the exposure outlet by gravimetric measurement for
micronised adenosine andmicronisedAMPonly, at a flow rate of
2 L/min. A superimposed flow of 225mL/minwas applied to the
pneumotachograph,which corresponds to the superimposed flow
needed to ensure that fresh aerosol is presented to the animals
during the in vivo exposure. The remaining 1775mL/min airflow
was drawn in through the air bypass on the impactor (see Fig. 1).
The fractions available for bronchial, alveolar and total lung de-
position were calculated using Multiple-Path Particle Dosimetry
Model software (ARA, USA) and a breathing simulation model
for the guinea pig (tidal volume 1.7 mL and 60 breaths/min).
Measurements were performed in triplicate. For each replicate
LC 
AC 
Connection to pressurised 
air (<10 bar) 
Connection to pressurised 







Cascade impactor exposure 





Fig. 1 The PreciseInhale system. A powder dose is loaded into the
loading chamber, which is then pushed through the nozzle by a high-
pressure air jet into the aerosol chamber, where it subsequently settles
by opposing force of gravity. It is then released towards the exposure
module, for which the flow is created by a vacuum pump. A light-
scattering device measures the particle density in the aerosol, which is
used to track the emitted dose. The exposure modules used in this study
were a Marple cascade impactor and intracheally intubated guinea pigs.
Various valves are present in the tubing to allow pressure build-up and
release as well as the air to flow in the correct direction. These have been
omitted for clarity. A more complete explanation of the PreciseInhale
system can be found in reference [17]. AC aerosol chamber, CI cascade
impactor, EF end filter, EXP exposure module, GP guinea pig, LC
loading chamber, LS light-scattering measuring device, NZ nozzle, PN
pneumotachograph, VP vacuum pump
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measurement, loadingofmultiple consecutivedoseswas required
to obtain the full dose (ten for adenosine, five for AMP).
Bronchial challenge in allergic guinea pigs
Animals
Male Dunkin–Hartley guinea pigs (400–450 g; Harlan, UK)
were used throughout this study. Guinea pigs were housed on-
site for at least 7 days prior to experimentation and given free
access to food and water. They were maintained in cages con-
taining bedding and enrichment with a 12-h day/night cycle.
All studies were carried out under the UK Animals (Scientific
Procedures) Act of 1986.
Passive sensitisation
The procedure for passive sensitisation of the guinea pigs has
been described previously [14], although a lower dose of oval-
bumin was administered in this study with a similar level of
sensitisation. Ovalbumin was dissolved in saline (5 mg/mL)
and mixed with aluminium hydroxide solution (v/v 1:10).
This solution was injected intraperitoneally (i.p.) into recipients
(1 mg/kg) on day 0 and again on day 10. On day 17, blood was
collected via a cannula inserted into the carotid artery under i.p.
anaesthesia with urethane (1.75 g/kg) and added to heparin
(0.2 mL; 100 U/mL). Blood was centrifuged (2000×g for
15 min) and the plasma collected and stored at − 20 °C until
further use. For passive sensitisation, this anti-ovalbumin guin-
ea pig plasma was injected intravenously (i.v.) via the saphe-
nous vein of recipient naïve conscious guinea pigs (1 mL per
animal). Passively sensitised guinea pigs received an
ovalbumin challenge (10 mg/mL for 1 h) 1 day prior to airway
responsiveness assessment on days 7–10 (post injection).
Anaesthetic protocol
Guinea pigs were placed in an induction chamber and exposed
to isoflurane (5%; 2 L/min). Once laterally incumbent, ani-
mals were removed from the chamber and isoflurane contin-
ued to be administered via a facemask. Adequate anaesthesia
was achieved when guinea pigs no longer responded to a toe
pinch. Isoflurane was then reduced to 3% (2 L/min). A mid-
line incision was subsequently made in the neck of the guinea
pig. The jugular vein was cannulated for i.v. administration of
propofol. Isoflurane was then withdrawn and 100 μL propofol
was slowly infused over 3 min, after which it was continuous-
ly infused (3mL/h) using an infusion pump. The carotid artery
was cannulated for heart rate and blood pressure measure-
ments. The trachea was cannulated for attachment to the
PreciseInhale system and ventilator. In Fig. 2, a schematic
overview of the new anaesthetic protocol is given.
Dose calculations
The highest nebulised dose was based on previous studies
using 10 mg/mL AMP [14], which equals to 7.7 mg/mL
adenosine in terms of molarity. The highest dry powder
doses of 215 μg adenosine and 280 μg AMP were calcu-
lated to correspond to the highest nebulised doses based on
nebuliser output rate (0.34 mL/min), inhalation time (10 s)
and inspiratory fraction of the respiratory cycle (0.50). The
highest i.v. doses (0.77 mg/kg adenosine and 1 mg/kg
AMP) were based on preliminary studies that established
an increase in resistance of approximately 100% above
isoflurane
isoflurane
i.v. cannula inserted  
in jugular vein 
propofol
infusion pump connected to i.v. cannula 
isoflurane
withdrawn 
Fig. 2 Schematic presentation of
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baseline. Three dose levels (10, 50 and 100% of highest
dose) were administered per delivery method.
Measurement of airway responsiveness
In total, 18 groups of animals (two compounds × three deliv-
ery methods × three doses) were tested, with three to four
animals in each test group. Six groups of animals were ex-
posed to dry powder aerosols of micronised adenosine or
micronised AMP via the PreciseInhale system. The tracheal
cannula was connected to the outlet of the aerosol chamber
(see Fig. 1), and animals were monitored for 2–3 min before
aerosol exposure to ensure stable spontaneous breathing.
After exposure, these animals were transferred to a heated
mat and the cannula was then attached to the ventilator and
pneumotachograph to record lung function parameters (see
Fig. 3). The animals were artificially ventilated at a rate of
60 breaths/min and 1 mL air/100 g body weight. Six groups
were exposed to adenosine or AMP via nebulised aerosol
(Aeroneb, Aerogen, USA), and six further groups received
adenosine or AMP i.v., all of these whilst on the ventilator at
the same ventilation rate and tidal volume. For the
nebulisation procedure, 1 mL of solution was added to the
nebuliser. Once activated, the ventilator flow was turned
(using a three-way tap) to pass through the nebuliser, which
then forced the nebulised solution into the lungs for 10 s. The
nebuliser was switched off and the ventilator flow changed
back to flow directly to the animal (Fig. 3). Total lung resis-
tance (RL), dynamic lung compliance (Cdyn) and mean arterial
blood pressure were recorded before and after adenosine re-
ceptor agonist administration using a pneumotachograph and
pressure transducer (Validyne Engineering, USA) and auto-
mated lung function recording system (Pulmonary
Monitoring System, version 9.2; Mumed, UK) as described
previously [14].
Data analysis
Airway obstruction was calculated as % increase in RL above
baseline and % decrease in Cdyn below baseline, for which the
individual animal’s own baseline values were used. Data are
expressed asmean ± standard error of the mean (SEM). Due to
the exploratory nature of the study, no power analysis was
performed to determine the group size. Rather, three to four
animals per group were tested to ensure sufficient data per
group for observing trends, in case any of the groups
contained a non-responding animal. No formal statistical anal-
ysis was performed either.
Results
Dry powder characterisation
The primary PSDs of spray-dried (adenosine and AMP) and
micronised (adenosine, AMP and CPA) powders are shown in
Table 1. All powders largely consisted of particles in the re-
spirable size range (< 5 μm), and both spray-dried powders
and the three micronised powders had very similar size
distributions.
DSC thermograms (heat flow versus temperature) of the
adenosine receptor agonists as received and after spray drying
or micronisation (Fig. 4) indicated that all starting materials
showed one endothermal peak corresponding to the melting
temperature of that compound (adenosine 236 °C, AMP
191 °C, CPA 105 °C), which was followed by degradation
(exothermal event) in the case of AMP. AMP furthermore
exhibited a step in the baseline (change in heat capacity) at
96 °C, which is considered to be a transition of amorphous
content from glass into rubbery state. The thermograms of
micronised adenosine and AMP were comparable to their
starting materials. However, micronised CPA exhibited an
guinea pig 
PC 
intrathoracic cannula to  
measure TPP 
arterial cannula to record BP 
venous cannula 
for i.v. dose 







Fig. 3 Schematic presentation of
the integrated experimental setup
for ventilation, nebulised aerosol
administration and measurement
of the pulmonary function of the
guinea pigs. BP blood pressure,
TPP transpulmonary pressure
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additional thermal event at 87 °C, suggesting a glass transi-
tion. The energy that is expended during the endothermal
event (melting) at 105 °C is lower compared to the starting
material, confirming that the crystalline content of the powder
is reduced. Spray-dried adenosine and spray-dried AMP also
exhibited a transitory thermal event at 100 and 96 °C, respec-
tively. Amorphous adenosine content then underwent
crystallisation (exothermal event) at 140 °C and subsequent
melting (endothermal event) at 237 °C. For spray-dried AMP,
the endothermal melting peak was not present, indicating this
powder was also (mostly) amorphous.
XRPD analysis confirmed that both adenosine and CPA as
received were fully crystalline; AMP as received and
micronised CPA were partly amorphous, partly crystalline
and spray-dried adenosine and spray-dried AMP were fully
amorphous (data not shown).
Dry powder dispersion with the PreciseInhale system
Five adenosine receptor agonist formulations were tested in
the PreciseInhale system. For three formulations, spray-dried
adenosine, spray-dried AMP and micronised CPA, an emitted
fraction < 1% was obtained. This was due to the formation of
hard agglomerates in the loading chamber of the PreciseInhale
system retaining over 90% of the loaded dose. Micronised
adenosine and micronised AMP were successfully dispersed
with emitted fractions of 10 and 27% respectively (Table 2).
Although micronised adenosine and AMP had very similar
primary PSDs, with a volume median diameter (VMD) of
1.42 and 1.40 μm, respectively (Table 1), the aerodynamic
PSD in the aerosol clouds from the PreciseInhale system were
Table 1 Primary particle size distributions of the adenosine receptor
agonist formulations
X10 (μm) X50 (μm) X90 (μm) FPF< 5 μm (%)
Spray-dried
Adenosine 1.03 2.19 3.97 96.7
AMP 0.83 2.25 4.84 91.2
Micronised
Adenosine 0.66 1.42 2.93 100
AMP 0.65 1.40 3.38 100
CPA 0.66 1.42 3.03 100
X10, X50 and X90 represent the 10, 50 and 90% values from the cumula-
tive volume undersize curve; the X50 value equals the volume median
diameter (VMD). Data obtained with RODOS dispersion at 3 bar. n = 2,
only the mean is shown because the variation is very low
AMP adenosine 5′-monophosphate, CPA 6 N-cyclopentyladenosine,
FPF<5 μm fine particle fraction <5 μm as percentage of the delivered dose
Fig. 4 Differential scanning calorimetry thermograms of adenosine, adenosine 5′-monophosphate (AMP) and N6-cyclopentyladenosine (CPA) starting
materials (red) and after micronisation (green) or spray drying (blue). Offset on the y-axis has been used for presentation purposes and clarity
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different (Fig. 5), with AMP exhibiting a mass median aero-
dynamic diameter (MMAD) of 1.8 μm and adenosine an
MMAD of 3.2 μm. Since adenosine had a lower emitted frac-
tion, this difference in PSDmay be due to the loss of the finest
fraction (< 1 μm) in the aerosol chamber by diffusive deposi-
tion on the wall of the chamber. Since very fine particles are
also likely to be exhaled, the total lung deposition fraction was
calculated to be higher for adenosine than for AMP, which
was reflected in the target doses to be administered to obtain
the desired deposited dose (452 μg for adenosine and 900 μg
for AMP) (Table 2).
Bronchial challenge in vivo
Administration of both adenosine (Fig. 6) and AMP (Fig. 7)
caused a dose-dependent increase in airway obstruction (RL)
in sensitised guinea pigs when administered by each of the
delivery methods. Obstruction of the lower airways
(expressed in Cdyn) exhibited a corresponding dose-
dependent decrease in all groups (data not shown). The differ-
ences in the magnitude of responses produced by the three
administration methods reflected differences in dose; the larg-
est dose was delivered by i.v. (e.g., a guinea pig weighing
400 g received 308 μg adenosine and 400 μg AMP), followed
by dry powder aerosol (215 μg adenosine and 280 μg AMP),
and the dose delivered by nebulisation was presumably the
lowest. Based on the values reported by the manufacturer
(MMAD 2.1 μm, GSD 2.2 [18]), the deposited fraction from
the nebulised aerosol is estimated to be 35%, which corre-
sponds to doses of 75 μg adenosine and 98 μg AMP.
Although the dry powder dose was based on the estimated
dose delivered by nebulisation, the latter was not corrected
for nebulised droplet size or exhaled fraction prior to experi-
mentation, factors that the PreciseInhale system does take into
account in calculating the (much higher) target dose. Thus,
adenosine delivered using the PreciseInhale system produced
a greater level of airway obstruction compared to the maxi-
mum dose administered via nebulisation. I.v. administration of
adenosine achieved the greatest level of airway obstruction,
although this route of administration is limited in practice due
to greater systemic effects as adenosine receptor agonists
cause a significant decrease in blood pressure, an effect
minimised by selecting a route of administration targeting
the adenosine directly to the lungs [14].
Discussion
In this study, apre-clinicalmodel for studyingairway respon-
siveness was developed based on aerosol administration of
Table 2 Aerosol characteristics and performance parameters of dry powder dispersion with the PreciseInhale system used to calculate the target top













Adenosine 10 3.2 1.8 48 70:30 215 452
AMP 27 1.8 2.2 31 63:37 280 900
Emitted fraction and MMAD (and GSD) were obtained from the PreciseInhale system. Total lung deposition fraction and the ratio bronchial/alveolar
deposition were calculated using Multiple-Path Particle Dosimetry Model software (ARA, USA)
AMP adenosine 5′-monophosphate, GSD geometric standard deviation, MMAD median mass aerodynamic diameter
Fig. 5 Aerodynamic particle size distribution of the delivered dose of
adenosine (left) and adenosine 5′-monophosphate (AMP; right)
generated with the PreciseInhale system obtained with cascade
impaction analysis. The dotted line indicates the mass median
aerodynamic diameter (MMAD). n = 3, mean ± SD shown
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dry powder formulations of adenosine receptor agonists to
spontaneously breathing, unconscious guinea pigs. To
achieve this using the PreciseInhale technique required the
development of a novel anaesthetic regime for guinea pigs,
which was robust and allowed the animals to spontaneously
breathe for the duration of the experiment.
For delivery of dry powder aerosols, the PreciseInhale
system effectively dispersed micronised formulations of
adenosine and AMP. However, it failed to disperse spray-
dried formulations of these compounds or a micronised for-
mulation of another adenosine receptor agonist, CPA. This
was likely due to crystallisation of amorphous content (in the
presence of a small percentage of residual water) in the pow-
der upon applying the high-pressure pulse (100 bar) [19],
which was used to disperse the powder into an aerosol cloud
in the PreciseInhale system. During crystallisation, solid-
state bridges were formed, resulting in hard agglomerates
that were too large to be dispersed through the nozzle into
the aerosol chamber.Reducing the pressure to 70 bar resulted
in a slightly higher emitted fraction for micronised CPA,
providing evidence for this crystallisation hypothesis.
However, the emitted fraction for CPA was still below 1%
and powder retention in the loading chamber was over 90%.
Therefore, this compound in the formulation used was con-
sidered inappropriate for use with the current system.
Formulationmodifications such as the addition of stabilising
excipients (e.g., sugars) or dispersion enhancers (e.g., leu-
cineormagnesiumstearate) could be explored to increase the
emitted fraction. Additionally, system modifications could
be made to produce powder aerosols using lower pressures
where physical stability to high pressure is an issue. It would
also be useful to develop a module to deliver liquid
(nebuliser) aerosols to enable direct comparisons of different
aerosol formulations using accurately controlled doses via a
common delivery platform.
The micronised adenosine and AMP formulations were
dispersed by the PreciseInhale system with no noticeable
changes to the (minute) powder residues in the loading cham-
ber of the system.Nevertheless, the emitted fractionswere10
and 27% for adenosine and AMP respectively. For relatively
inexpensive compounds like adenosine and AMP, low emit-
ted fractions do not necessarily pose a problem, as long as the
results are reproducible. However, for more expensive com-
pounds, low emitted fractions may be unacceptable, espe-
cially considering the further losses that occur during admin-
istration of the aerosols to animals. The system produces an
aerosol that is presented to the animal continuously.
However, since the animal breathes spontaneously in this
setup, only during inspiration does the aerosol actually de-
posit in the lungs, and of those aerosolised particles that are
available for deposition in the lungs, yet another fractionwill
be exhaled. Consequently, the amount of powder needed to
be fed into the system was larger still, with 10–15 mg aden-
osine needed to obtain the desired deposited dose of 215 μg
per animal (effectivedeposition1–2%of loadeddose) and7–
10 mg AMP for a deposited dose of 280 μg (effective depo-
sition 3–4% of loaded dose).
Respirable aerosol exposure in small animals is a great
challenge. Intratracheal delivery via instillation of liquid
sprays or powders deliver drug to the lungs with less losses
compared to nasal or intratracheal inhalation of respirable
aerosols, but at the expense of uneven distribution of the
test material in the lungs [20–22]. With respiratory aerosol
exposures supplying fresh aerosols to avoid rebreathing of
aerosol, there is a theoretical maximum delivered dose of
50% based on the inhalation-exhalation breathing cycle
[23], which converts to an upper limit of ~ 25% in rodents
using intratracheal inhalation when the deposition fraction
is applied. However, this often decreases to below 10% if
typical losses to equipment deposition are included.
Although the system delivers a dose of aerosol Befficiently^
to an individual animal, there were issues with the time
Fig. 7 Dose-dependent responses in total lung resistance (RL) to
adenosine 5′-monophosphate (AMP) administered via PreciseInhale dry
powder aerosol, nebulised aerosol or i.v. injection. n = 3–4, mean ± SEM
shown
Fig. 6 Dose-dependent responses in total lung resistance (RL) to
adenosine administered via PreciseInhale dry powder aerosol, nebulised
aerosol or i.v. injection. n = 3–4, mean ± SEM shown
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required to deliver the dose and interfacing the apparatus for
aerosol delivery with that for measuring lung function. This
may have been the reason why the dose-dependent increase
that was observed with adenosine could not be seen with
AMP. AMP was less effective at causing airway obstruction
compared with adenosine and indeed administration as a
powder did not achieve a significant level of airway obstruc-
tion. This may be due to the longer time (> 12 min) required
for delivery of the full dose, which could have been so long
that it partly overlapped with the onset and maxima of the
compound’s bronchoconstrictive effects. As the animals had
to be transferred from the PreciseInhale system to the venti-
lator for the lung function measurement, it is likely that the
maximumeffect wasmissed for the highest AMPdoses. One
of the drawbacks of the current system is the inability to
monitor lung function simultaneously with administering
compounds through the Prec ise Inhale sys tem to
intratracheally cannulated or intubated animals, although
the manufacturer of the system has indicated that they are
working on integrating lung function measurements into
the equipment (personal communication). Nonetheless, the
current setup does allow for bronchoactive compounds (e.g.,
bronchodilators) to be administered directly to the lungs to
determine the time course of the bronchoprotective effect
when the spasmogen is subsequently administered by
nebulisation whilst the animal is on the ventilator.
Furthermore, there is scope for nose-only administration
through the PreciseInhale system, which may allow for
studying chronic exposure of powders to animals, as surgery
would not be required.
The system’s advanced feedback system, based on mea-
surement of light scattering at the outlet of the aerosol
chamber, enables improved control of the dose that is ad-
ministered to the individual animals. The key advantage of
this feedback system is that it leads to reduction of the
variation of delivered dose per animal [20], which is espe-
cially important in toxicological and pharmacokinetic stud-
ies. Reduced variability in delivered dose should also lead
to less variability in effect, but the group sizes in this
proof-of-concept study were too small to formally assess
whether a reduct ion in var ia t ion was obta ined.
Additionally, bronchoconstriction may not be the best out-
come measure to evaluate variability because of large inter-
individual variation in airway responsiveness.
In conclusion, we have confirmed that inhalation of
adenosine and AMP caused airway obstruction in sponta-
neously breathing, unconscious, ovalbumin-sensitised
guinea pigs, whether these compounds are administered
by solution or dry powder aerosol into the lungs. The
PreciseInhale system accurately administered micronised
powder aerosols directly to the lungs of individual guinea
pigs, although some powders were not physically stable
due to high-pressure dispersion.
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